ArticleInflammopharmacology2025
Amelioration of pain and adjuvant-induced arthritis by syringic acid via modulation of behavioral parameters and inflammatory mediators i.e. TNF-α, Interleukins, MCP-1, NF-kB and COX-2.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antinociceptive and Anti-Inflammatory Effects of Syringic Acid:ACS omega · 2026Article
- Syringic Acid in Health and Disease: Mechanisms, Biological Activities, and Future Perspectives.International journal of molecular sciences · 2026Review
- A drug-drug co-amorphous formulation for enhanced solubility and transdermal absorption of rotundine.International journal of pharmaceutics: X · 2026Article
- Design, Synthesis, and Evaluation of New 2-Arylpropanoic Acid-l-Tryptophan Derivatives for Mitigating Cisplatin-Induced Nephrotoxicity.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syringic acid with reported anti-inflammatory attribute was investigated in the present study to assess its anti-arthritic potential at doses of 25 mg/kg, 50 mg/kg and 100 mg/kg using adjuvant-induced arthritic rats. The rat's paw size (mm), arthritic index and behavioral parameters were observed at baseline and subsequently at seven days' interval until the completion of the study, following complete Freund's adjuvant (CFA) induction. The animals were anesthetized on 28th day and blood samples were obtained for the determination of numerous biochemical, hematological, pro-inflammatory, anti-inflammatory and oxidative biomarkers. Afterwards, the weight of lymphoid organs and radiographic, as well as histopathological examinations of the inflamed paw, were conducted. Furthermore, molecular docking was done to find out the interaction between syringic acid and Interleukins-1β, tumor necrosis factor-α, Interleukins-6 (IL-6), Interleukins-4 (IL-4) and Cyclooxygenase-2 (Cox-2). Results revealed that chronic syringic acid administration significantly reduced the paw size, arthritic index, and showed improvement in behavioral parameters with retrieval of altered hematological and biochemical parameters. Treatment with syringic acid also exhibited substantial recovery from oxidative stress markers and lymphoid organ weight was retrieved. Upon quantitative real-time polymerase chain reaction (qRT-PCR) examination, syringic acid significantly reduced the mRNA expression of tumor necrosis factor-α and all the other inflammatory cytokines while enhancing the mRNA expression of anti-inflammatory cytokines. Decreased serum concentration of PGE2 was noted with syringic acid as determined by enzyme-linked immunosorbent assay (ELISA). Histopathological analysis and radiographs further confirmed the findings. Molecular docking studies showed good interaction between syringic acid and IL-1β, tumor necrosis factor-α, IL-6, IL-4 and COX-2 when compared against standard.
Indexed as
Identifiers
40332704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.